Purchase this article with an account.
Teemu Mäkitie, Paula Summanen, Ahti Tarkkanen, Tero Kivelä; Tumor-Infiltrating Macrophages (CD68+ Cells) and Prognosis in Malignant Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2001;42(7):1414-1421.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. To investigate the hypothesis that tumor-infiltrating macrophages
contribute to prognosis of uveal melanoma and to study their
association with tumor characteristics, especially microvessels.
methods. This was a retrospective, population-based cohort study of 167
consecutive patients who had had an eye with choroidal and ciliary body
melanoma removed between 1972 and 1981. Macrophages were identified
with mAb PG-M1 to the CD68 epitope, and their number and morphologic
type were recorded. Kaplan-Meier and Cox regression analyses of
melanoma-specific survival were performed.
results. CD68-positive macrophages could be assessed in 139 (83%) of the 167
melanomas. Their number was moderate to high in 115 (83%) of the 139
tumors, and their morphology ranged from dendritic to round. A high
number of macrophages was associated with presence of epithelioid cells
(P = 0.025), heavy pigmentation
(P = 0.001), and high microvascular density
(P = 0.001). The 10-year melanoma-specific
mortality rate increased with higher numbers of macrophages (0.10 for
low versus 0.57 for high numbers, P = 0.0012). The
morphologic type of infiltrating macrophages was not associated with
mortality. The number of macrophages was modeled by stratification,
which significantly improved a Cox regression model
(P < 0.001). Adjusting for the other independent
indicators of metastatic death 10-year melanoma-specific mortality was
0.17 for low versus 0.45 for high numbers of macrophages.
conclusions. The number of tumor-infiltrating CD68-positive macrophages contributes
to prognosis and associates with cell type and microvascular density,
which merits a further analysis of the biological role of these cells
in uveal melanoma.
This PDF is available to Subscribers Only